Stenting for iliac vein stenosis or compression has become a common therapeutic approach in recent years. The antithrombotic therapy after the stent deployment, however, reaches no consensus. Medications strategies and patients' prognoses differ in non-thrombotic, acute thrombotic and chronic thrombotic these three circumstances. Non-thrombotic patients usually possess satisfactory stent patency whatever antithrombotic therapy is used. Anticoagulant is the basic medication for acute thrombotic patients, benefits from additional antiplatelet drug remains to be clarified. In terms of chronic thrombotic patients, their prognoses are unsatisfactory under all antithrombotic therapies. In this review, we outlined the recent progress of antithrombotic therapy after iliac vein stenting, aiming to provide feasible medication plans for each circumstance.
近年来支架植入治疗髂静脉狭窄或压迫已有普及趋势，但支架治疗术后抗凝血药和抗血小板药的选择尚无共识。针对非血栓性、急性血栓性和慢性血栓性髂静脉狭窄或压迫这三种不同情况，患者术后用药方案和预后也不尽相同。非血栓性患者无论采用何种抗凝、抗血小板策略，支架通畅率均较满意；急性血栓性患者以抗凝为基础，联用抗血小板药能否额外获益有待进一步探讨；而慢性血栓性患者在不同用药策略下预后均较差。本文就患者术后不同用药方案作一综述，以期为最佳用药策略提供思路。